Therapeutic interventions that target fundamental mechanisms of aging are being sought to radically transform public health. Indicators of biological aging that can be identified prior to overt manifestations of late-life conditions, and concomitantly serve as predictors of future health and longevity, could facilitate this effort. As highlighted in this RFA, resilience, defined as the ability of an organism to adequately respond to physical challenges, may offer one such opportunity. Thus, the objective of this proposal is to develop and validate a battery of disease-agnostic physical challenges to enable the evaluation of resiliency in mice. To this end, in Specific Aim 1 we will determine which physical challenges best reveal differences in resilience between and within younger, middle-aged, and older mice. Specifically, we will assess acute responses to anesthesia, chemotherapy, surgery, and dehydration in cohorts of 4-month-old, 12-month-old, and 20-month-old mice.
In Specific Aim 2, using the physical challenges deemed optimal in Specific Aim 1, we will determine the extent to which baseline resilience of middle-aged mice longitudinally predicts healthspan using discriminating measures of physical, metabolic, cardiovascular, and immune function at Mayo Clinic, and lifespan at the University of Michigan. Given the considerable evidence that aberrant mTOR signaling and senescent cell accumulation are mediators of aging, in Specific Aim 3 we will determine the extent to which rapamycin and targeted clearance of p16INK4a-positive senescent cells affect the resilience of older mice to physical challenges. We expect that a standardized battery of clinically relevant measures of resilience in laboratory mice will provide a new framework in which to test innovative and potentially transformative interventions to promote healthy aging. In humans, the emergence of chronic diseases and syndromes such as frailty may reflect a point of no return. Compromised resilience earlier in life, on the other hand, may ultimately serve as a therapeutic opportunity in which the progression of aging-related molecular and cellular damage can be attenuated, if not reversed.

Public Health Relevance

The ability of an organism to adequately respond to physical challenges or stress, termed resilience, may reflect its biological age before there is evidence of chronic disease or other late-life conditions. Herein, we propose to develop standardized physical challenges of resilience for laboratory mice, determine the degree to which they predict future health and longevity, and assess the extent to which they respond to innovative therapies that have been shown to delay aspects of aging.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG053832-03
Application #
9478014
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Macchiarini, Francesca
Project Start
2016-08-15
Project End
2021-04-30
Budget Start
2018-05-15
Budget End
2019-04-30
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Schafer, Marissa J; Miller, Jordan D; LeBrasseur, Nathan K (2017) Cellular senescence: Implications for metabolic disease. Mol Cell Endocrinol 455:93-102
Schafer, Marissa J; White, Thomas A; Iijima, Koji et al. (2017) Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 8:14532
Sritharen, Yoginee; Enriquez-Sarano, Maurice; Schaff, Hartzell V et al. (2017) Pathophysiology of Aortic Valve Stenosis: Is It Both Fibrocalcific and Sex Specific? Physiology (Bethesda) 32:182-196
Casaclang-Verzosa, Grace; Enriquez-Sarano, Maurice; Villaraga, Hector R et al. (2017) Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice. J Vis Exp :
Zhou, Dan; Hlady, Ryan A; Schafer, Marissa J et al. (2017) High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 12:55-69